Published in Nat Struct Biol on April 01, 1995
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol (2012) 2.67
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J Proteome Res (2007) 2.61
DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J (1999) 2.50
Improving the quality of NMR and crystallographic protein structures by means of a conformational database potential derived from structure databases. Protein Sci (1996) 2.33
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A (2008) 2.14
How p53 binds DNA as a tetramer. EMBO J (1998) 1.82
New methods of structure refinement for macromolecular structure determination by NMR. Proc Natl Acad Sci U S A (1998) 1.79
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci U S A (2006) 1.59
Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A (2009) 1.46
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J (1998) 1.39
Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A (2006) 1.37
Determination of the structures of symmetric protein oligomers from NMR chemical shifts and residual dipolar couplings. J Am Chem Soc (2011) 1.35
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J (2006) 1.26
Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J (2000) 1.26
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family. BMC Genomics (2009) 1.16
Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. Proc Natl Acad Sci U S A (1999) 1.15
Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2009) 1.13
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J (2011) 1.10
ENPDA: an evolutionary structure-based de novo peptide design algorithm. J Comput Aided Mol Des (2005) 1.05
Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol (2011) 1.04
p53 mutations and expression in breast carcinoma in situ. Am J Pathol (2000) 0.99
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry (2006) 0.98
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
p53 RNA interactions: new clues in an old mystery. RNA (2007) 0.97
Backbone dynamics of the oligomerization domain of p53 determined from 15N NMR relaxation measurements. Protein Sci (1995) 0.95
Protein complexes studied by NMR spectroscopy. Curr Opin Biotechnol (1996) 0.95
Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. Protein Sci (1999) 0.95
Protein phi and psi dihedral restraints determined from multidimensional hypersurface correlations of backbone chemical shifts and their use in the determination of protein tertiary structures. J Biomol NMR (1997) 0.93
Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface. Proc Natl Acad Sci U S A (2005) 0.93
Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system. RNA (2006) 0.91
Assignment of 1H(N), 15N, 13C(alpha), 13CO and 13C(beta) resonances in a 67 kDa p53 dimer using 4D-TROSY NMR spectroscopy. J Biomol NMR (2000) 0.90
Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J (1997) 0.90
Structure and kinetic stability of the p63 tetramerization domain. J Mol Biol (2011) 0.88
An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes. Mol Cell Biol (1999) 0.88
Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils. Protein Sci (2005) 0.86
Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry (2010) 0.86
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. Cell Cycle (2016) 0.85
Domain-domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy. Proc Natl Acad Sci U S A (2012) 0.83
A fluid salt-bridging cluster and the stabilization of p53. J Mol Biol (2007) 0.83
Soft-shell clam (Mya arenaria) p53: a structural and functional comparison to human p53. Gene (2008) 0.82
Molecular dynamics of the full-length p53 monomer. Cell Cycle (2013) 0.82
A unified assembly mode revealed by the structures of tetrameric L27 domain complexes formed by mLin-2/mLin-7 and Patj/Pals1 scaffold proteins. Proc Natl Acad Sci U S A (2005) 0.82
Cellular adaptation to hypoxia and p53 transcription regulation. J Zhejiang Univ Sci B (2009) 0.81
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem (2010) 0.80
Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr (2008) 0.80
Tracing the evolution of the p53 tetramerization domain. Structure (2014) 0.79
Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Mol Oncol (2014) 0.78
Topology Engineering of Proteins in Vivo Using Genetically Encoded, Mechanically Interlocking SpyX Modules for Enhanced Stability. ACS Cent Sci (2017) 0.77
Quaternary structure of p53: the light at the end of the tunnel. Proc Natl Acad Sci U S A (2007) 0.76
Utilizing NMR to study the structure of growth-inhibitory proteins. Methods Mol Biol (2003) 0.75
Meanfield approach to the thermodynamics of protein-solvent systems with application to p53. Biophys J (2001) 0.75
The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site. Protein Sci (2008) 0.75
Ironing out the angles in p53. Nat Struct Biol (1995) 0.75
Design of a molecular support for cryo-EM structure determination. Proc Natl Acad Sci U S A (2016) 0.75
SpotOn: High Accuracy Identification of Protein-Protein Interface Hot-Spots. Sci Rep (2017) 0.75
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science (1992) 8.68
DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 7.78
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A (1987) 6.90
The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science (1989) 6.89
Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A (1981) 6.67
Solution structure of a calmodulin-target peptide complex by multidimensional NMR. Science (1992) 6.16
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science (1992) 5.99
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 5.76
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett (1989) 4.75
Rapid analysis of amino acid phenylthiohydantoins by high-performance liquid chromatography. Anal Biochem (1977) 4.64
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med (1989) 3.89
Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J (1998) 3.77
NMR structure of a specific DNA complex of Zn-containing DNA binding domain of GATA-1. Science (1993) 3.74
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1990) 3.53
Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations. FEBS Lett (1988) 3.49
Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J (1999) 3.46
Multidimensional heteronuclear nuclear magnetic resonance of proteins. Methods Enzymol (1994) 3.45
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J (2001) 3.37
Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell (1995) 3.35
Isolation and characterization of linear deoxyribonucleic acid plasmids from Kluyveromyces lactis and the plasmid-associated killer character. J Bacteriol (1981) 3.30
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature (2001) 3.25
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J (1992) 3.21
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A (1997) 3.19
Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol (1992) 3.10
Demonstration of positionally disordered water within a protein hydrophobic cavity by NMR. Science (1995) 3.02
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science (1994) 2.98
The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat Struct Biol (1996) 2.94
DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy. Nucleic Acids Res (1987) 2.93
Structures of larger proteins in solution: three- and four-dimensional heteronuclear NMR spectroscopy. Science (1991) 2.84
Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol (1997) 2.81
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry (1995) 2.69
The solution structure of a specific GAGA factor-DNA complex reveals a modular binding mode. Nat Struct Biol (1997) 2.67
Isolation and characterization of four plasmids from Bacillus subtilis. J Bacteriol (1977) 2.59
Contribution of antigen-presenting cell major histocompatibility complex gene products to the specificity of antigen-induced T cell activation. J Exp Med (1982) 2.58
The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif. Nat Struct Biol (1997) 2.56
Use of dipolar 1H-15N and 1H-13C couplings in the structure determination of magnetically oriented macromolecules in solution. Nat Struct Biol (1997) 2.51
Determining the structures of large proteins and protein complexes by NMR. Trends Biotechnol (1998) 2.49
Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer. J Immunol (1983) 2.45
Intracellular crowding defines the mode and sequence of substrate uptake by Escherichia coli and constrains its metabolic activity. Proc Natl Acad Sci U S A (2007) 2.42
Identification of a binding site for the human immunodeficiency virus type 1 nucleocapsid protein. Proc Natl Acad Sci U S A (1993) 2.41
Direct structure refinement against residual dipolar couplings in the presence of rhombicity of unknown magnitude. J Magn Reson (1998) 2.40
Three-dimensional structure of interleukin 8 in solution. Biochemistry (1990) 2.40
Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med (1990) 2.40
Intercalation, DNA kinking, and the control of transcription. Science (1996) 2.39
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
A robust method for determining the magnitude of the fully asymmetric alignment tensor of oriented macromolecules in the absence of structural information. J Magn Reson (1998) 2.38
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J (2000) 2.38
Analysis of the backbone dynamics of interleukin-1 beta using two-dimensional inverse detected heteronuclear 15N-1H NMR spectroscopy. Biochemistry (1990) 2.36
Improving the quality of NMR and crystallographic protein structures by means of a conformational database potential derived from structure databases. Protein Sci (1996) 2.33
Improvements and extensions in the conformational database potential for the refinement of NMR and X-ray structures of proteins and nucleic acids. J Magn Reson (1997) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Four-dimensional heteronuclear triple-resonance NMR spectroscopy of interleukin-1 beta in solution. Science (1990) 2.28
Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells. Proc Natl Acad Sci U S A (1981) 2.22
Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol (1998) 2.19
Design of an expression system for detecting folded protein domains and mapping macromolecular interactions by NMR. Protein Sci (1997) 2.16
Clonal rat parathyroid cell line expresses a parathyroid hormone-related peptide but not parathyroid hormone itself. Biochem Biophys Res Commun (1989) 2.15
Amino acid sequences of two mouse immunoglobulin lambda chains. Proc Natl Acad Sci U S A (1971) 2.12
Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol (1989) 2.12
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11